NeOnc Q3 net loss $8.6M ($0.45/diluted); NEO100 Phase 2a shows 21% response rate; board changes

NEONC TECHNOLOGIES HOLDINGS, INC.

2025-Q3 EPS reported -$2.48 revenue$39,990

Net loss of $8.6M ($0.45 diluted EPS) vs $2.2M ($0.12) in Q3 2024; G&A up $903k vs $244k YoY.
NEO100 Phase 2a in recurrent brain cancer: 21% response rate vs <8% historical; 44% six-month PFS; 33% alive >=18 months.
NEO212 received FDA authorization to proceed to Phase II; Phase I final cohort dosing on track for Q4 2025.
NuroMENA subsidiary signed $50M strategic partnership with Quazar Investment, appointed H.H. Sheikh Nahyan as Exec Chairman.
Dr. Ming-Fu Chiang re-elected to Board after Ishwar K. Puri resigned due to USC objection.

item 2.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.